Nucleotide analogue antiviral
Cidofovir
Brand names: Vistide
Adult dose
Dose: Induction: 5mg/kg IV weekly for 2 weeks. Maintenance: 5mg/kg every 2 weeks. Each dose with probenecid + IV hydration
Route: IV
Frequency: weekly/q2w
Clinical pearls
- CMV retinitis in AIDS — second-line. Mandatory probenecid and saline pre-hydration to reduce nephrotoxicity
Contraindications
- Severe renal impairment
- Hypersensitivity to probenecid/sulphonamides
Side effects
- Nephrotoxicity (dose-limiting)
- Neutropenia
- Ocular hypotony
- Metabolic acidosis
Interactions
- Other nephrotoxic drugs (aminoglycosides, amphotericin, NSAIDs, foscarnet)
Monitoring
- U&E and urinary protein before each dose
- FBC
- Visual acuity
- IOP
Reference: BNF; https://bnf.nice.org.uk/drugs/cidofovir/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023